Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA Adverse Event Reporting System.
CONCLUSION: When prescribing PD-1 inhibitors, physicians should monitor closely for symptoms of bullous pemphigoid.
PMID: 31088310 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Databases & Libraries | Dermatology | Drugs & Pharmacology | Pemphigoid | Skin | Statistics | Toxicology